Program
seltorexant
Also written as “JNJ-42847922”, “Seltorexant” and “JNJ-42847922, 5 mg”.
Its studies are mostly in Depressive Disorder, Major · Sleep Initiation and Maintenance Disorders · Alzheimer Disease · Sleep Apnea, Obstructive · Renal Insufficiency, led by Johnson & Johnson.
Drug pageSeltorexant: every studyAll 32 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 332 open or running | phase 3since Aug 13, 2020 | Jan 22, 2014 | Dec 30, 2026phase 3 · NCT06559306 |
- Named in Johnson & Johnson’s own pipeline as
seltorexant
, phase 3, as of Oct 13, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 17 earlier studies, Jan 22, 2014 to Dec 4, 2017.
- Jun 9, 2016Named seltorexantINNProposed as its International Nonproprietary Name in WHO's List 115 · before, JNJ-42847922
- Feb 8, 2018Phase 1 study in HealthyNCT03438461 · 49 enrolled · United States
- Apr 5, 2018Phase 1 study in HealthyNCT03494907 · 52 enrolled · Belgium
- Sep 21, 2018Phase 1 study in HealthyNCT03682380 · 151 enrolled · United States
- Jan 4, 2019Phase 1 study in Sleep Apnea, ObstructiveNCT03796026 · 34 enrolled · United States
- Jun 26, 2020Phase 1 study in Depressive Disorder, MajorNCT04451187 · 63 enrolled · Belgium, Germany
- Aug 13, 20203 phase 3 studies in Depressive Disorder, MajorNCT04513912, NCT04533529, NCT04532749
- Sep 14, 2020Phase 1 study in HealthyNCT04553042 · 69 enrolled · United States
- Nov 2, 2020Phase 1 study in Renal InsufficiencyNCT04616677 · 24 enrolled · United States
- Jun 30, 2021Phase 1 study in Depressive Disorder, MajorNCT04951609 · 31 enrolled · United States, Italy, Spain and more
- Jul 2, 2021Phase 1 study in HealthyNCT04960124 · 24 enrolled · Germany
- Feb 2, 2022Phase 1 study in HealthyNCT05236868 · 10 enrolled · Netherlands
- Mar 25, 2022Phase 2 study in Alzheimer DiseaseNCT05307692 · 88 enrolled · United States
- Aug 15, 2024Phase 3 study in Depressive Disorder, MajorNCT06559306 · 752 planned · United States, Argentina, Brazil and more
- May 1, 2026Phase 3 study in Depressive Disorder, MajorNCT07573176 · 600 planned · United States, Argentina, Brazil and more
Ahead
- Dec 30, 2026Primary completion: phase 3 study in Depressive Disorder, MajorNCT06559306
- Aug 24, 2028Primary completion: phase 3 study in Depressive Disorder, MajorNCT07573176
TargetBeta
“Orexin receptor 2 antagonist”ChEMBL 37, by rule
Other programs on HCRTR2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| daridorexantrule | Idorsia Pharmaceuticals | phase 4 | 34 |
| HS-10506 | Hansoh Pharmaceutical Group | phase 3 | 6 |
| cleminorexton | Eli Lilly | phase 3 | 1 |
Studies
All 33 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07573176Depressive Disorder, Major · United States, Argentina, Brazil and more | 3 | Recruiting | Aug 24, 2028 | 600 |
| NCT06559306Depressive Disorder, Major · United States, Argentina, Brazil and more | 3 | Recruiting | Dec 30, 2026 | 752 |
| NCT05307692Alzheimer Disease · United States | 2 | Completed | Nov 10, 2023 | 88 |
| NCT05236868Healthy · Netherlands | 1 | Completed | Mar 1, 2022 | 10 |
| NCT04960124Healthy · Germany | 1 | Completed | Nov 19, 2021 | 24 |
| NCT04951609Depressive Disorder, Major · United States, Italy, Spain and more | 1 | Terminated | Apr 8, 2024 | 31 |
| NCT04616677Renal Insufficiency · United States | 1 | Completed | Oct 18, 2022 | 24 |
| NCT04553042Healthy · United States | 1 | Completed | Dec 20, 2020 | 69 |
| NCT04532749Depressive Disorder, Major · United States, Argentina, Chile and more | 3 | Terminated | May 24, 2022 | 212 |
| NCT04533529Depressive Disorder, Major · United States, Brazil, Bulgaria and more | 3 | Completed | Apr 25, 2023 | 588 |
| NCT04513912Depressive Disorder, Major · United States, Argentina, Belgium and more | 3 | Completed | Oct 3, 2023 | 757 |
| NCT04451187Depressive Disorder, Major · Belgium, Germany | 1 | Completed | Mar 16, 2023 | 63 |
| NCT03796026Sleep Apnea, Obstructive · United States | 1 | Completed | Jun 7, 2019 | 34 |
| NCT03682380Healthy · United States | 1 | Completed | Aug 23, 2019 | 151 |
| NCT03494907Healthy · Belgium | 1 | Completed | Aug 13, 2018 | 52 |
| NCT03438461Healthy · United States | 1 | Completed | May 30, 2018 | 49 |
| NCT03374475Depressive Disorder, Major · United States, Belgium, Germany and more | 1 | Completed | Apr 29, 2019 | 140 |
| NCT03375203Sleep Initiation and Maintenance Disorders · United States, Belgium, France and more | 2 | Completed | Apr 3, 2019 | 365 |
| NCT03321526Depressive Disorder, Major · United States | 2 | Completed | Jun 13, 2019 | 107 |
| NCT03249402Healthy · Belgium | 1 | Completed | Nov 24, 2017 | 24 |
| NCT03227224Depressive Disorder, Major · United States, Bulgaria, Finland and more | 2 | Completed | Jan 12, 2019 | 287 |
| NCT03025022Healthy · United States | 1 | Completed | Feb 27, 2017 | 8 |
| NCT02837692Healthy · United States | 1 | Completed | Sep 7, 2017 | 140 |
| NCT02661893Healthy · United States | 1 | Completed | Feb 2016 | 14 |
| NCT02617810Healthy · United States | 1 | Completed | Feb 2016 | 18 |
| NCT02578472Healthy · Netherlands | 1 | Completed | Feb 2016 | 36 |
| NCT02555124Healthy · Japan | 1 | Completed | Oct 31, 2015 | 24 |
| NCT02475161Healthy · United States | 1 | Completed | Jul 2015 | 16 |
| NCT02464046Sleep Initiation and Maintenance Disorders · United States, Germany, Netherlands | 2 | Completed | Dec 2, 2015 | 28 |
| NCT02476058Depressive Disorder, Major · Belgium, Germany, Netherlands | 1 | Completed | Jan 4, 2016 | 48 |
| NCT02455856Healthy · Germany | 1 | Completed | Jun 19, 2015 | 16 |
| NCT02230878Healthy · Germany | 1 | Completed | Nov 2014 | 40 |
| NCT02067299Depressive Disorder, Major · Germany, Netherlands | 1 | Completed | Dec 2014 | 20 |
How it is read
Names in the registry
- “JNJ-42847922”, 13 entries
- “Seltorexant”, 10 entries
- “JNJ-42847922, 5 mg”, 2 entries
- “JNJ-42847922, 20 mg”, 2 entries
- “Seltorexant 40 mg”, 2 entries
Conditions, from the studies’ own filings
- Depressive Disorder, Major, 12 studies
- Sleep Initiation and Maintenance Disorders, 2 studies
- Alzheimer Disease, 1 study
- Sleep Apnea, Obstructive, 1 study
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.